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Abstract 
It has been proposed that osteocyte viability plays an important role in bone integrity, 
and that bone loss in osteoporosis may be partially due to osteocyte cell death 
following estrogen depletion. Osteoporosis treatments such as bisphosphonates can 
inhibit osteocyte apoptosis which in turn may also reduce remodelling. Consequently, 
microcracks in bone which are normally repaired by bone remodelling may 
accumulate. This study used an ovine model of osteoporosis to examine the effects of 
estrogen depletion and bisphosphonates on osteocyte apoptosis and microdamage 
accumulation.  
Skeletally mature ewes were randomly assigned into two equal groups; ovariectomy 
(OVX) and a non-treatment group (control). Half of these animals were sacrificed 
twelve months post-OVX. 20 months post-OVX, a number of OVX animals were 
randomly selected and each received a supra-pharmacological dose of the 
bisphosphonate, zoledronic acid (Zol). This group and all the remaining animals were 
sacrificed 31 months post-OVX. A compact bone specimen was removed from the 
left metacarpal of each animal; half was used for osteocyte apoptosis detection and 
the remainder for microdamage analysis.  
Estrogen deficiency resulted in significant increases in the levels of osteocyte 
apoptosis while zoledronic acid significantly reduced the level of apoptosis in 
osteocytes. Zoledronic acid treatment resulted in the formation of more microcracks. 
However, these cracks were shorter than in control or OVX groups which may 
provide one explanation as to why increased damage levels following bisphosphonate 
treatment have not lead to increased fractures. This study also provides additional 
evidence of the importance of estrogen in preserving the osteocyte network.  
Key Words: Osteoporosis, Ovine, Osteocyte, Apoptosis, Microcrack,Bisphosphonate 
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Introduction 
Although there are a number of factors involved in determining the risk of developing 
osteoporosis, the end result is an imbalance between resorption by osteoclasts and 
formation by the osteoblasts. The consequence of which is a loss of bone resulting in 
fracture and for this reason most treatments for the disease focus primarily on 
preventing osteoclast activity. However, it has been suggested that osteocyte viability 
may also play a significant role in the maintenance and integrity of bone, and that 
bone loss in osteoporosis may be due in part to osteocyte cell death following 
estrogen depletion. (1,2) Previous studies have found that estrogens prevent the 
apoptosis of osteocytes. (3-5) Studies have also linked osteocyte apoptosis to the 
initiation of the bone remodelling process and that osteocyte density decreases with 
age. (6,7) All of these studies imply that estrogens and the osteocyte network play an 
integral part in maintaining bone equilibrium. 
Bone microdamage accumulation has been implicated in osteoporotic fractures and 
increasing skeletal fragility. (8) Through the repair of microdamage, bone remodelling 
not only prevents the accumulation of old fragile bone but also results in the 
formation of new viable osteocytes. (9) Experimentally a strong association between 
microdamage, osteocyte apoptosis, and bone remodelling has been demonstrated. (7) 
This supports the hypothesis that osteocyte apoptosis provides a key part of the 
activation or signalling mechanisms by which osteoclasts target bone for remodelling.  
Bisphosphonates are a family of drugs which have proven successful in preventing 
bone loss and reducing fracture risk in osteoporosis. Etidronate has been shown to 
preserve bone mass in healthy postmenopausal women (10-12) and to increase bone 
mineral density (BMD) in the spine and hip. (13,14) Alendronate has also been found to 
substantially reduce the frequency of fractures among women with low bone mass and 
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existing vertebral fractures.(15) Similarly, zoledronic acid increases BMD in 
postmenopausal women (16) and improves bone structure and mechanical strength in 
the long bones of ovariectomised rats. (17) Zoledronic acid also prevents loss of bone 
structure and mechanical strength in vertebral bone in ovariectomised rats. (18) 
Bisphosphonates work by inhibiting osteoclast bone resorption. (19) However, part of 
their success may also lie in their capacity to preserve the mechanosensitive osteocyte 
network. Bisphosphonates have been shown to have an anti-apoptotic affect on 
osteocytes both in vivo and in vitro,(20) along with causing the apoptosis of osteoclasts. 
(21,22)
 More recently risedronate has also been shown to suppress osteocyte apoptosis 
induced by fatigue loading of the ulna in rats. (23) One possible problem with 
bisphosphonates suppressing bone remodelling is in relation to microdamage 
accumulation. As the removal of microdamage is an integral part of remodelling, 
preventing this process from occurring can result in the accumulation of 
microdamage. A number of studies have found that suppression of bone remodelling 
by bisphosphonates increases microdamage accumulation. (24-27)  
 
Aim 
The aim of this study was to identify the effects of estrogen withdrawal following 
ovariectomy and a supra-pharmacological dose of zoledronic acid on the levels of 
osteocyte apoptosis and microdamage in an ovine model of osteoporosis.  
 
Materials and Methods 
Animal Model 
Sixty-four skeletally mature (> 4years), mixed breed ewes were randomly assigned 
into an ovariectomy (OVX, n=32) or control group (n=32) on which no operative 
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procedure was carried out. Twelve months post-OVX, half of each group were 
sacrificed. A further eight months later (following 20 months of estrogen deficiency) 
four OVX animals were randomly selected to serve as a third group, OVX plus 
zoledronic acid (Zol; Novartis Pharma). Each animal received a 5mg dose of 
zoledronic acid in 100mls of saline infused over 30 minutes. This procedure was 
repeated for a further four weeks, giving each animal a 25mg dose. Following 
administration of the drug, the animals were returned to pasture. All remaining 
animals were sacrificed 31 months post-OVX, approximately one year following 
administration of zoledronic acid. 
 
Apoptosis Staining 
Following sacrifice a 3cm thick block of bone was removed from the distal end of the 
left metacarpal and fixed in 10% formalin. The samples were then decalcified by 
agitating in 0.5M ethylenediamine tetraacetic acid (EDTA), pH 7.2 at 4°C with a 
change of solution every 3 days. Once decalcified, samples were embedded in 
paraffin wax and cut to a thickness of 7µm using a microtome (Leica RM2255, Leica 
Microsystems, Germany) and placed on poly-L lysine coated slides. To detect 
apoptotic cells, the slides were stained using a DeadEnd Fluorometric terminal 
deoxynucleotidyl transferase-mediated dUTP- biotin nick end labeling (TUNEL) 
system (Promega Corporation, Madison, WI).  The fluorescein-12-dUTP labelled 
deoxyribonucleic acid (DNA) was visualised directly by fluorescence microscopy 
using a standard fluorescein excitation and emission filter at 520+/- 20nm. Both a 
positive and a negative control were included in the staining process. For the positive 
control, DNase (RQ1 Dnase, MSC, Dublin, Ireland) was used to cleave DNA. The 
negative control was prepared using autoclaved water in place of the rTdT enzyme. A 
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mounting medium containing 4',6-diamidino-2-phenylindole (DAPI) was used to stain 
the nuclei of all cells. Two sections from each bone sample were analysed.  
 
Microdamage Detection 
Adjacent to the block removed for apoptosis, a 3cm block of bone was removed from 
the distal end of the metacarpal. The sample was en bloc stained in basic fuchsin (28) 
before 100µm thick transverse sections were cut. Two slides from each sample were 
viewed using fluorescence microscopy and microcracks were identified using a 
previously described technique. (28)   
Statistical Analysis 
Results are presented as mean ± standard deviation. Results were tested for normality 
using the SPSS software package (SPSS Inc, Chicago, IL). ANOVA and the Mann-
Whitney rank sum tests were used to determine statistical significance. A p value of ≤ 
0.05 was considered to be significant unless otherwise stated.  
 
Results 
In this study there was no significant change in the osteocyte density following 
ovariectomy or zoledronic acid treatment (Table 1). After 12 months the control 
group had a value of 402±147mm-2 while in the OVX group that value was 
442±95mm-2. At 31 months the density in the control group was 489±100mm-2, in the 
OVX group the density was 550±98mm-2 and in the Zol group it was 506±46mm-2. 
However a significant increase in the level of osteocyte apoptosis was found in the 
OVX group relative to the control group at both time points (Figure 1). At 12 months 
approximately 1% of the osteocytes in the control group were undergoing apoptosis. 
Following ovariectomy this value rose to 10%.  After 31 months there was no change 
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in the level of apoptosis in the control group, remaining at 1%. However at this later 
time point the level of apoptosis in the OVX group had increased to 15%.  The results 
showed that there was no significant change in the level of apoptosis between the 
control groups over time. However, the levels of apoptosis were significantly higher 
at 31 months than at 12 months in the OVX group.  Figure 1 also shows the anti-
apoptotic effect that zoledronic acid had on osteocytes. Treatment with zoledronic 
acid resulted in a reduction in the level of osteocyte apoptosis, down to 3%.  
No significant difference was found in the mean microcrack density between the 
control and OVX groups at either time point (Figure 3). In the 12 month group the 
mean crack density in the control group was 0.045±0.040mm-2 and in the OVX group 
it was 0.036±0.042mm-2. In the 31 month group, the mean microcrack density in the 
controls was 0.040±0.045mm-2 and 0.055±0.043mm-2 in OVX group. There was no 
significant change in mean crack density in the control group over time (p=0.08). 
There was no significant increase detected in mean crack density in the OVX group 
over time, (p=0.07). In the Zol group, the crack density of 0.225±0.043mm-2 was 
significantly greater (p≤0.005) than either the control or OVX groups. 
In the 12 month group there was no significant difference in the mean microcrack 
length between the two groups (Figure 4). The mean crack length in the control group 
was 151±47µm and in the OVX group it was 122±28µm. In the 31 month group again 
there was no significant difference in the mean crack length between the control 
(148±35µm) and OVX (130±29µm) groups. However, the average crack length was 
significantly less in the Zol treated animals (84±25µm). There was no significant 
difference in mean crack length over time in either the control or OVX groups. 
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Discussion 
This study found that estrogen withdrawal significantly increases the level of 
osteocyte apoptosis as early as 12 months. However, changes in microdamage 
accumulation are only becoming apparent after 31 months. Zoledronic acid treatment 
was shown to reduce the level of osteocyte apoptosis following estrogen withdrawal. 
Zoledronic acid treatment also significantly increased microdamage levels while 
significantly reducing the mean length of these cracks relative to both control and 
OVX groups.  
 
Ovariectomy is often used as a model of post-menopausal osteoporosis. In sheep, 12 
months of estrogen deficiency following ovariectomy leads to significant reductions 
in bone mineral density with changes seen as early as 6 months post OVX. (29) In the 
current study the time points were chosen to reflect changes previously reported. The 
initial 12 month group coincides with known BMD decreases. In order to maximise 
the changes seen following estrogen deficiency, the animals were left at pasture for a 
further eight months before zoledronic acid was administered (20 months post-OVX). 
As zoledronic acid is an annual treatment the animals were euthanized approximately 
12 months later, providing the second time point of 31 months.  
 
Sheep bone is primarily plexiform bone up until the age of 3-4 years (30) after 
which Haversian remodelled bone becomes more prevalent. (31) At the starting point 
of this experiment our animals were 4+ years of age. Therefore, at the time points 
chosen (12 and 31 months post OVX) animals were 5+ years and approximately 
7+ years of age.  From other work carried out by our group, histological images from 
the metatarsal of the same animals show secondary osteons in the control group at 12 
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months, indicative of secondary remodelling occurring. (32) Another study by our 
group which examined the effects of bone turnover on crack behavior following 
fatigue testing found no significant difference in crack density between the control 
and OVX groups (after 12 months) in cracks <100um and between 100 and 300um 
long. (33) As most cracks which occur under normal physiological loading conditions 
(as was the case in the current study) fall within this range, we can assume that 
although some plexiform bone may remain this has little or no bearing on the current 
results and our ovine model is an accurate representation of the human condition.  
 
The current prescribed dose of zoledronic acid for osteoporosis treatment is 5mg 
delivered as one dose annually. (34) As mature sheep have a similar weight and bone 
size to adults, 5mg annually can also be considered a clinical dose in sheep. However, 
patients receiving zoledronic acid for breast cancer treatment can receive a dose up to 
270mg. (35) Bisphosphonates prevent bone turnover and as a result it is proposed that 
microdamage will accumulate following treatment with bisphosphonates. Therefore, 
the current study used a supra-pharmacological dose to reduce bone turnover and 
produce a marked microdamage accumulation in our small experimental group. 
 
This study found no significant difference in the total number of osteocytes between 
the control and OVX groups. This is consistent with previous work which found that 
ovariectomy in sheep did not produce a significant change in osteocyte density. (36) In 
the current study, the level of osteocyte apoptosis was significantly greater in the 
OVX groups relative to the control groups. This increase in osteocyte apoptosis 
following ovariectomy indicates the importance of estrogens in maintaining osteocyte 
viability. In rats it has been shown that ovariectomy resulted in an increase of 
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osteocyte apoptosis from 2.3% in sham operated animals to 10% in ovariectomised 
animals. (37) This is consistent with the changes in the current study where 
ovariectomy induced apoptosis from a level of approximately 1% in the control group 
to 10% in the ovariectomy group after 12 months, rising to 15% after 31 months. 
Zoledronic acid treatment produced an anti-apoptotic effect, reducing levels to 
approximately 3%.  
 
While most studies on microdamage tend to examine the ribs or long bones such as 
the femur or tibia, in the current study the metacarpal was chosen for analysis. In 
sheep, unlike in humans, the metacarpal is a load bearing bone which is perpendicular 
to the ground when the animal is standing. Therefore, it is subject to continual fatigue 
loading, optimal conditions under which to produce microdamage. While this study 
found no significant difference in microdamage levels between the control and OVX 
groups, the values are consistent with previously reported data. The current study 
found crack values in the region 0.04 mm-2 and in vivo crack densities in the region of 
0.012-0.074mm-2 have been reported in sheep radii. (38) Similar values were reported 
in dogs with densities of between 0.042 and 0.073mm-2 reported in the femur. (39) In 
human metatarsals microcrack densities of 0.23±0.15mm-2 and 0.35±0.19mm-2 have 
been reported in cadaveric samples (40) while in young males and females, crack 
densities in femoral compact bone of approximately 0.1-0.2mm-2 have been 
measured. (41) Therefore the values found in this study are consistent with both human 
and animal studies which determined in vivo crack densities.  
 
In the current study it appears that prolonged estrogen deficiency may result in an 
increase in the mean microcrack density over time (between 12 and 31 month OVX 
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groups, p=0.07). In related studies carried out by our group using the same animals, 
the bone turnover was examined in the left metatarsal.(32,42) These works found that in 
the ovariectomised animals there was a significant increase in bone turnover at 12 and 
31 months. Therefore, it is hypothesised that the increased turnover is removing 
damage and may explain why no significant difference in crack density levels are 
seen between the control and OVX groups. However, turnover has slowed down in 
the 31 month OVX group relative to the 12 month group and there is a trend towards 
increased microcrack density between the 12 and 31 month OVX groups (p=0.07).  
 
The current work also found an increase in crack density in those animals treated with 
zoledronic acid. Bisphosphonates have previously been reported to increase crack 
density and crack surface density at both clinical and supraclinical doses. (24-26,43,44) 
Bisphosphonates prevent bone resorption, thereby older bone can accumulate which 
may result in an increase in damages levels as microcracks are not being removed. 
One reason why increased damage levels found following bisphosphonate therapy has 
not led to increased fragility following long term treatment might be partially 
explained by the current study. Although zoledronic acid treatment produced more 
cracks, the cracks that were formed were significantly shorter than those found in 
either the control or OVX groups. This might be explained by our understanding of 
microcrack growth and bone microstructure. The lamellar structure of osteons has 
been proposed as a mechanism to stop cracks produced by cyclic loading. (45) 
Subsequent to this the microstructure of cortical bone has been shown to have a 
significant influence on the propagation and initiation of microcracks. (46) In the 
ovariectomised group, the increased remodelling has resulted in the formation of extra 
secondary osteons. In a related study on the metatarsals of these animals, fatigue 
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loading ex vivo showed that cracks grew to significantly longer lengths in the control 
bone than they did in the ovariectomised bone. (33) In the current study the animals 
which received zoledronic acid had been ovariectomised 20 months prior to treatment. 
This provided an opportunity for the formation of a large number of osteons which 
might act as barriers to crack propagation and result in short cracks. Studies in our 
laboratory have also shown the existence of a microstructural barrier effect in bone. 
(47,48)
 This concept describes how cracks not only slow down or stop at microstructural 
features, such as resorption cavities or osteons but that they also initiate easily in 
weaker areas, such as lamellar interfaces. It has previously been demonstrated that 
microdamage also initiates more readily in highly mineralised areas of bone. (49) As 
bisphosphonates increase bone mineralisation, the animals which were treated with 
zoledronic acid have more potential for the formation of microcracks. Therefore a 
supra-clinical dose of zoledronic acid following estrogen deficiency appears to 
encourage the formation of numerous small cracks and minimise the formation of 
larger, detrimental cracks.  
 
This study has a number of limitations, one of which is that due to institutional ethical 
guidelines, a sham operated group was not used and rather a non-operated control was 
included. This was unlikely to have significantly impacted on this study, in particular 
limb loading, as those animals which underwent ovariectomy were subject to 
anaesthesia for a short period of time (<30mins) and once the anaesthesia had worn 
off, the animals were immediately mobile. The animals used in this study were also of 
mixed breed. There was no significant difference in bone mineral density or weight 
(data not shown here) between the breeds and therefore all animals were combined. 
However, it is possible that the variables examined in this study may be influenced by 
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breed and thus having a mixed population may affect the results.  The total number of 
samples tested per group also differed due to the small sample size of the zoledronic 
acid treated group. While this is a limitation, the strong statistical significance seen 
would likely only be improved using larger sample sizes. The animals in this group 
also received a suprapharmalogical dose of zoledronic acid. As the aim of this study 
was to determine the effects of ovariectomy (increased bone turnover) and zoledronic 
acid treatment (reduced bone turnover) on microdamage accumulation and osteocyte 
apoptosis a high dose was necessary to achieve a near complete cessation of bone 
turnover. This study identified microdamage using fuchsin bulk staining and 
epifluorescence microscope which visualises the cracks in two-dimensions. Other 
studies have used alternative fluorochromes such as calcein which have a more 
specific binding than fuchsin.(50-53) There has also been a trend towards examining 
microdamage in three-dimensions using confocal microscopy. (47,50,54,55) Both of these 
techniques may help to eliminate any erroneous labelling of artefacts as microcracks. 
Nonetheless, basic fuchsin labelling remains the gold standard in the field. 
 
Conclusion 
Overall this study has demonstrated that estrogen withdrawal is accompanied by 
increased osteocyte apoptosis and that osteocyte viability can be preserved by 
zoledronic acid treatment. While zoledronic acid treatment was found to increase 
microdamage accumulation, the cracks produced are significantly shorter than in the 
control or ovariectomised groups.  
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Table 1: Mean (± standard deviation) osteocyte density, % apoptotic osteocytes, 
microcrack density and microcrack length measured in sheep metacarpi 
following estrogen deficiency and zoledronic acid treatment. 
 
 12 Months 31 Months 
 Control OVX Control OVX Zol 
Osteocyte 
Density (mm-2) 402 ± 147 442 ± 95 489 ± 100 550 ± 98 506 ± 46 
% Apoptotic 
Osteocytes 0.8 ± 0.5 9.7 ± 3.0 
a
 0.4 ± 1.4 14.7 ± 4.6 a,c 3.3 ± 5.6 b 
Mean Crack 
Density (mm-2) 0.045 ± 0.04 0.038 ± 0.04 0.049 ± 0.05 0.052 ± 0.05 0.227 ± 0.09 
a
 
Mean Crack 
Length (µm-2) 151 ± 48 126 ± 27 140 ± 35 132 ± 29 84 ± 33 
a
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Figure 1: TUNEL staining found a significant increase in the level of osteocyte 
apoptosis in the OVX group relative to control at both 12 and 31 months post-OVX 
(a, p≤0.005). The % apoptosis in the OVX group increased over time with a 
significant increase after 31 months relative to 12 months post-OVX (c, p≤0.05). 
Treatment with zoledronic acid significantly reduced the level of apoptosis (b, 
p≤0.05).  
 
Figure 2: Fuchsin stained microcrack (white arrow) viewed using green incident light. 
  
Figure 3: Mean microcrack density was significantly higher in the zoledronic acid 
treatment group than any other (a, p≤0.005). 
 
Figure 4: The mean microcrack length was significantly lower following treatment 
with zoledronic acid than in any other group (a, p<0.05). 
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